Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer’s Association International Conference (AAIC) 2025
(NASDAQ:BIIB), TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI(R)), an anti-AB protofibril* antibody, […]